HK Stock Market Move | Grand Pharma (00512) surged over 4% as Yigantai received FDA approval to expand its indications for hepatocellular carcinoma (HCC), which is expected to lead to high growth in the company's performance.

GRAND PHARMA (00512) rose more than 4%, as of the time of writing, it has risen by 4.6% to HKD 9.78, with a trading volume of HKD 260 million. On the news front, on July 7th, Yttrium-90 (90Y) microsphere injection was granted early official approval by the US FDA for a new indication for unresectable hepatocellular carcinoma (HCC), without restrictions on tumor diameter size. This makes Yttrium-90 (90Y) microspheres the world's first and only selective internal radiotherapy product approved by the FDA for dual indications of unresectable HCC and liver metastases from colorectal cancer. Soochow pointed out that the demand for nuclear medicine continues to expand with aging populations and increasing cancer incidence rates, driving the expansion of the corresponding diagnostic and therapeutic market. Since 2018, GRAND PHARMA has accelerated the integration of the nuclear medicine sector, jointly conducting research and development in the RDC field with top international companies such as Telix, ITM, and Sirtex. The core commercial product Yttrium-90 (90Y) microspheres are expected to grow by over 140% by 2024, thanks to the training of over 1,100 doctors from more than 70 hospitals and the inclusion in 45 government medical insurance programs; based on this accumulation, we believe Yttrium-90 (90Y) will continue to bring high growth.